SPOR COV
/ Destiny Pharma, SporeGen
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
August 09, 2023
Safety Evaluation of Intranasal Use of DSM 32444 Postbiotic in Humans
(clinicaltrials.gov)
- P=N/A | N=60 | Completed | Sponsor: Huro Biotech Joint Stock Company
New trial • Otorhinolaryngology • Respiratory Diseases • Sinusitis
September 24, 2022
Intranasal Treatment of Ferrets with Inert Bacterial Spores Reduces Disease Caused by a Challenging H7N9 Avian Influenza Virus.
(PubMed, Vaccines (Basel))
- "The temporal kinetics of viral shedding was reduced but not prevented. Taken together, nasal dosing using heat-stable spores could provide a useful approach for influenza prophylaxis in both humans and animals."
Journal • Immunology • Infectious Disease • Respiratory Diseases
1 to 2
Of
2
Go to page
1